Input 2021.03.25 15:23
Kwon Joon-wook, head of the 2nd vice president of the Centers for Disease Control and Prevention (Bang Dae-bon), held a regular briefing on Corona 19 at the Centers for Disease Control and Prevention in Osong, Chungcheongbuk-do on the afternoon of the 25th, saying, “Analysis of the neutralization efficacy of 9 genotypes (mutations) of domestic viruses at the cellular level Neutralizing antibodies against the target genotype were detected.”
Plasma extracted from the blood of a cure for Corona 19 contains antibodies against the virus. Blood devices are made using antibodies in this plasma. Among antibodies, neutralizing antibodies play a role in defeating the Corona 19 virus.
The major corona19 genotypes used in this cell experiment were’S, L, V, G, GR, GH, GV, and British and South African mutations’. In the case of the Brazilian mutant strain, it is currently being isolated and cultured, so it was decided to analyze the efficacy separately in the future.
“It was confirmed that (these treatments) were hardly affected by the mutant virus. The actual treatment efficacy needs to be reviewed based on the clinical results of the pharmaceutical company,” said Kwon, head of the 2nd division. “In the medical field, the Ministry of Food and Drug Safety treatment It is recommended to use it according to the purpose of use approval,” he said.
The results of the phase 2 clinical analysis of the corona19 blood system will be announced next month.
In the case of blood system drugs, 42 cases are being used for treatment purposes other than clinical trial purposes. The use for treatment purposes other than clinical trial purposes is a system that allows the use of drugs for clinical trials that are not licensed for the treatment of severe, life-threatening patients or without other means when treating diseases.